Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.67
-0.20 (-1.80%)
At close: Jun 26, 2026, 4:00 PM EDT
10.66
0.00 (-0.05%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Telix Pharmaceuticals.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Telix Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Financial Forecast
Revenue This Year
913.08M
from 803.79M
Increased by 13.60%
Revenue Next Year
1.07B
from 913.08M
Increased by 17.15%
EPS This Year
0.01
from -0.02
EPS Next Year
0.08
from 0.01
Increased by 1,050.61%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 933.7M | 1.2B | |
| Avg | 913.1M | 1.1B | |
| Low | 890.7M | 965.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 16.2% | 30.7% | |
| Avg | 13.6% | 17.1% | |
| Low | 10.8% | 5.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.07 | 0.28 | |
| Avg | 0.01 | 0.08 | |
| Low | -0.04 | -0.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 4,096.3% | |
| Avg | - | 1,050.6% | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.